Form 11-K ELI LILLY & Co For: Dec 31

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Form 11-K ELI LILLY & Co For: Dec 31

Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)

June 23, 2025 12:14 PM EDT

Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,133.00 price target on Eli Lilly (NYSE: LLY).

The analyst comments "One of the side effects of the dramatic weight loss of GLP-1 based medications is that people also lose muscle/lean body mass. LLY, REGN, BHVN and other companies are developing drugs targeting the activin receptor pathway with the goal of preventing/slowing muscle mass loss. LLY's program broadly blocks the receptors (and hence activins, myostatin, and GDF11 ligands simultaneously), while REGN is focused on selectively blocking two ligands (myostatin and activin A)... More